Renaissance Technologies
CARM

Renaissance Technologies’s Carisma Therapeutics CARM Stock Holding History

Renaissance Technologies’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-293,686
Closed -$80.5K – 3276
2025
Q3 		$80.5K Sell
293,686
-35,600
-11% -$11.8K ﹤0.01% 3282
2025
Q2 		$129K Buy
329,286
+75,629
+30% +$20.2K ﹤0.01% 3260
2025
Q1 		$78.6K Buy
253,657
+22,300
+10% +$9.88K ﹤0.01% 3228
2024
Q4 		$96.9K Buy
231,357
+24,600
+12% +$20.3K ﹤0.01% 3290
2024
Q3 		$203K Buy
206,757
+67,397
+48% +$73K ﹤0.01% 3122
2024
Q2 		$212K Sell
139,360
-86,635
-38% -$129K ﹤0.01% 3026
2024
Q1 		$513K Buy
225,995
+12,961
+6% +$31.1K ﹤0.01% 2855
2023
Q4 		$624K Buy
213,034
+8,339
+4% +$24.8K ﹤0.01% 2680
2023
Q3 		$866K Buy
204,695
+102,935
+101% +$651K ﹤0.01% 2400
2023
Q2 		$892K Buy
101,760
+33,465
+49% +$182K ﹤0.01% 2539
2023
Q1 		$212K Buy
68,295
+17,347
+34% +$165K ﹤0.01% 3252
2022
Q4 		$621K Sell
50,948
-1,842
-3% -$19.3K ﹤0.01% 2821
2022
Q3 		$449K Buy
52,790
+22,090
+72% +$301K ﹤0.01% 2986
2022
Q2 		$498K Buy
30,700
+7,828
+34% +$89.6K ﹤0.01% 3168
2022
Q1 		$276K Buy
+22,872
New +$319K ﹤0.01% 3509
2021
Q4 		– Sell
-78,484
Closed -$1.25M – 3915
2021
Q3 		$1.25M Buy
78,484
+15,054
+24% +$722K ﹤0.01% 2430
2021
Q2 		$5.86M Sell
63,430
-123,965
-66% -$7.91M 0.01% 1534
2021
Q1 		$9.74M Buy
187,395
+41,844
+29% +$1.97M 0.01% 1216
2020
Q4 		$3.93M Buy
145,551
+44,705
+44% +$1.13M ﹤0.01% 1736
2020
Q3 		$2.82M Buy
100,846
+36,941
+58% +$739K ﹤0.01% 1917
2020
Q2 		$920K Buy
63,905
+53,494
+514% +$721K ﹤0.01% 2577
2020
Q1 		$117K Buy
+10,411
New +$171K ﹤0.01% 3197
2018
Q4 		– Sell
-700
Closed -$30K – 3387
2018
Q3 		$30K Sell
700
-801
-53% -$31.2K ﹤0.01% 3306
2018
Q2 		$59K Buy
+1,501
New +$66.1K ﹤0.01% 3179
2016
Q3 		– Sell
-5,925
Closed -$198K – 3335
2016
Q2 		$198K Buy
5,925
+300
+5% +$7.59K ﹤0.01% 3052
2016
Q1 		$36K Buy
+5,625
New +$77.8K ﹤0.01% 3300

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Renaissance Technologies's CARM Position: Q4 2025 in Review

Renaissance Technologies sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 293,686 shares — an estimated $80.5K sold.

Renaissance Technologies first reported a position in CARM in Q1 2016 and held it in 26 quarters. The position peaked at $9.74M in Q1 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Renaissance Technologies reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 293,686 Carisma Therapeutics shares in Q4 2025, an estimated $80.5K.
  • Renaissance Technologies first reported a position in Carisma Therapeutics in Q1 2016 and held it in 26 quarters.
  • Renaissance Technologies's Carisma Therapeutics position peaked at $9.74M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.